Trial Profile
The study for simeprevir, peg-interferon, and ribavirin treatment efficacy against the patients with chronic hepatitis C (Multicenter trial)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Nov 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 27 May 2015 New trial record